Literature DB >> 31368170

Optimal sequences of same-visit bidirectional endoscopy: Systematic review and meta-analysis.

Passisd Laoveeravat1,2, Subhanudh Thavaraputta1, Sakolwan Suchartlikitwong1, Wasawat Vutthikraivit1, Thammasak Mingbunjerdsuk1, Arunee Motes1, Kenneth Nugent1, Abhilash Perisetti3, Benjamin Tharian3, Sameer Islam1, Ariwan Rakvit1,4.   

Abstract

BACKGROUND AND AIM: Same-visit colonoscopy and esophagogastroduodenoscopy (EGD) have become common. Recent studies showed conflicting results regarding the performance, safety, and efficacy of different sequences. We conducted this meta-analysis to determine the most favorable performance and discomfort between an EGD followed by colonoscopy (E-C) and colonoscopy followed by EGD (C-E).
METHODS: The authors searched the databases of MEDLINE and EMBASE. Outcomes of interest were performance (including cecal intubation time, adenoma detection rate, and polyp detection rate), discomfort score (patients and endoscopists; Likert scale), and sedation uses. Pooled mean differences (MD) or odds ratios (OR) were calculated with 95% confidence intervals (CI).
RESULTS: Six randomized controlled trials were included in the meta-analysis. The authors found that there was significantly lower sedative use including fentanyl (14.70; 95% Cl: 8.20-21.20) and propofol (15.58; 95% Cl: 3.27-27.89) in the E-C group compared with the C-E group. There was a significantly better discomfort score in patients and endoscopists after both procedures in the E-C group than in the C-E group with pooled MD of 0.64 points (95% Cl: 0.09-1.20) and 0.47 (95% Cl: 0.05-0.90), respectively. There were no differences in cecal intubation time, adenoma detection rate, or polyp detection rate between the two groups.
CONCLUSION: The present study found that the discomfort score was better in the E-C group. However, there was no difference in polyp and adenoma detection. Therefore, the E-C group is the optimal sequence.
© 2019 Japan Gastroenterological Endoscopy Society.

Entities:  

Keywords:  bidirectional endoscopy; colonoscopy; discomfort; optimal sequence; upper endoscopy

Mesh:

Substances:

Year:  2019        PMID: 31368170     DOI: 10.1111/den.13503

Source DB:  PubMed          Journal:  Dig Endosc        ISSN: 0915-5635            Impact factor:   7.559


  5 in total

1.  Low-Dose Esketamine as an Adjuvant to Propofol Sedation for Same-Visit Bidirectional Endoscopy: Protocol for a Multicenter Randomized Controlled Trial.

Authors:  Nan Song; Xi-Sheng Shan; Yi Yang; Zhong Zheng; Wen-Cheng Shi; Xiao-Yan Yang; Yang Li; Ai-Ping Tan; Hong Liu; Ke Peng; Fu-Hai Ji
Journal:  Int J Gen Med       Date:  2022-05-06

2.  The Efficacy and Safety of Remimazolam Tosilate versus Etomidate-Propofol in Elderly Outpatients Undergoing Colonoscopy: A Prospective, Randomized, Single-Blind, Non-Inferiority Trial.

Authors:  Xianwen Liu; Baofeng Ding; Fu Shi; Yang Zhang; Lei Liu; Yongwei Sha; Tonghang Zhao
Journal:  Drug Des Devel Ther       Date:  2021-11-16       Impact factor: 4.162

3.  Esketamine as an Adjuvant to Ciprofol or Propofol Sedation for Same-Day Bidirectional Endoscopy: Protocol for a Randomized, Double-Blind, Controlled Trial With Factorial Design.

Authors:  Yu-Qin Long; Chang-Dong Feng; Yun-Ying Ding; Xiao-Mei Feng; Hong Liu; Fu-Hai Ji; Ke Peng
Journal:  Front Pharmacol       Date:  2022-03-18       Impact factor: 5.810

4.  Comparison of Procedural Sequences in Sedated Same-Day Bidirectional Endoscopy with Water-Exchange Colonoscopy: A Randomized Controlled Trial.

Authors:  Yu-Hsi Hsieh; Malcolm Koo; Chih-Wei Tseng
Journal:  J Clin Med       Date:  2022-03-02       Impact factor: 4.241

5.  Comparison of three sedation models for same-day painless bidirectional endoscopy: A multicenter randomized controlled trial.

Authors:  Yue Sui; Xing Chen; Ting Ma; Junhui Lu; Tao Xiao; Zhenzhen Wang; Qing Wen; Guanfeng Wang; Hui Jia; Fengzhen Cao; Xiaopeng Wu; Yiping Zhang; Junlian Hao; Naping Wang
Journal:  J Gastroenterol Hepatol       Date:  2022-06-02       Impact factor: 4.369

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.